Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide.
Lifecare's NOK30 price target is now front and center again, with the fair value assumption held at NOK0.40 while discount rate inputs and peer comparisons are being revisited. Analysts are lining up that NOK30 level against recent NOK30 or $30 targets for peers such as Ethos, using it as a reference point for how the market is thinking about risk and long term earnings potential in this space. As you read on, you will see how this evolving narrative, both bullish and cautious, might shape how you track Lifecare from here.
Stay updated as the Fair Value for Lifecare shifts by adding it to your watchlist or portfolio . Alternatively, explore our Community to discover new perspectives on Lifecare.
What Wall Street Has Been Saying
🐂 Bullish Takeaways
-
Recent research on peer company Ethos shows several firms, including Deutsche Bank, Baird and Citizens, lifting their price targets toward the $30 mark. This level is now being referenced alongside Lifecare's NOK30 framework as a rough yardstick for sector risk and return expectations.
-
Deutsche Bank's move to set a $30 target for Ethos, combined with target increases at Baird and Citizens, indicates that larger institutions are actively revisiting assumptions around earnings power and execution potential for companies grouped with Lifecare.
-
For readers tracking valuation, these higher Ethos targets provide a reference point for how some analysts think about longer term upside scenarios in similar business models, even as Lifecare's own fair value input of NOK0.40 remains under review.
🐻 Bearish Takeaways
-
The current review of Lifecare's discount rate assumptions and peer set also highlights that analysts are not simply importing Ethos-style $30 cases. Instead, they are emphasizing execution risks and the gap between present pricing and more optimistic scenarios.
-
With Lifecare's fair value assumption held at NOK0.40 while the NOK30 reference level is debated, the spread between these figures suggests that a significant portion of the long term story is still treated as unproven by parts of the market.
Do your thoughts align with the Bull or Bear Analysts? Perhaps you think there's more to the story. Head to the Simply Wall St Community to discover more perspectives!
We've flagged 5 risks for Lifecare. See which could impact your investment.
How This Changes the Fair Value For Lifecare
-
Fair value assumption is kept unchanged at NOK0.40.
-
Revenue growth assumption is kept effectively unchanged, with a decline of about 6.01% in both the prior and updated figures.
-
Net profit margin assumption is kept effectively unchanged at about 21.80%.
-
Future P/E multiple is kept broadly stable, moving marginally from 136.27x to 136.36x.
-
Discount rate has risen slightly from 7.81% to 7.83%.
Never Miss an Update: Follow The Narrative
Narratives connect Lifecare's clinical milestones, partnerships and operational decisions to the financial assumptions sitting behind its fair value. They refresh as new data, approvals and company updates come through, so you can see how the story shifts over time.
Head over to the Simply Wall St Community and follow the Narrative on Lifecare to stay up to date on:
-
How the collaboration with TTP on implant design and manufacturability could affect production efficiency and cost of goods over time.
-
What Lifecare's new sensor chemistry and potential Sanofi commercial rights activation might mean for glucose sensor adoption and market access, including a future push into Europe after CE marking.
-
The key execution risks around in vivo validation, scaling automated production, regulatory timing for CE marking and the possibility that the Sanofi partnership does not progress as planned.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include LIFE.OL .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
